Numata M, Minamida I, Yamaoka M, Shiraishi M, Miyawaki T
J Antibiot (Tokyo). 1978 Dec;31(12):1252-61. doi: 10.7164/antibiotics.31.1252.
New cephalosporins modified in the acyl part of 7-(3'-oxobutyrylamino)cephalosporins (1), which have been described in the preceding paper, were synthesized by thiolation at the 2'- or the 4'-position, or by transforming the 3'-oxo group into a 3'-imino group. The most active compound in vitro was 3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-7-(4-methylthio-3-oxobutyrylamino)ceph-3-em-4-carboxylic acid (7c), which showed superior in vitro activity against Gram-positive and Gram-negative bacteria compared to the parent cephalosporin (1b) with the same 3-substituent. The ED50 value for 7c, however, was essentially equal to that of 1b in mice infected with Escherichia coli O-111.
在前一篇论文中已描述过的7-(3'-氧代丁酰氨基)头孢菌素(1)的酰基部分经修饰的新型头孢菌素,是通过在2'-或4'-位进行硫醇化,或将3'-氧代基团转化为3'-亚氨基基团而合成的。体外活性最强的化合物是3-[[(1-甲基-1H-四氮唑-5-基)硫基]甲基]-7-(4-甲硫基-3-氧代丁酰氨基)头孢-3-烯-4-羧酸(7c),与具有相同3-取代基的母体头孢菌素(1b)相比,它对革兰氏阳性菌和革兰氏阴性菌显示出更强的体外活性。然而,在感染大肠杆菌O-111的小鼠中,7c的ED50值与1b基本相等。